NCT06725381View on ClinicalTrials.gov

A Phase 1 Study of SKB571 in Subjects with Advanced Solid Tumors

PHASE1Not yet recruitingINTERVENTIONAL

Enrollment

138

Participants

Timeline

Start Date

December 31, 2024

Primary Completion Date

December 31, 2026

Study Completion Date

December 31, 2027

Conditions

Solid Malignancies

Interventions

DRUG

SKB571

SKB571 for injection is administered every 3 weeks (q3w) until radiographic disease progression (PD), intolerable toxicity, death, or discontinuation of treatment, whichever occurs first.

All Listed Sponsors

lead

Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.

INDUSTRY